2023
Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles
Ganesh S, Lam T, Garcia-Milian R, D'Souza D, Nairn A, Elgert K, Eitan E, Ranganathan M. Peripheral signature of altered synaptic integrity in young onset cannabis use disorder: A proteomic study of circulating extracellular vesicles. The World Journal Of Biological Psychiatry 2023, 24: 603-613. PMID: 36994633, PMCID: PMC10471733, DOI: 10.1080/15622975.2023.2197039.Peer-Reviewed Original ResearchMeSH KeywordsExtracellular VesiclesHumansMarijuana AbusePilot ProjectsProteomicsSubstance-Related DisordersYoung AdultConceptsNeuron-derived extracellular vesiclesLabel-free quantification mass spectrometryProteomic studiesCannabis use disorderExtracellular vesiclesMass spectrometry proteomic analysisDifferential proteomic profilesAdapter proteinProteomic analysisPost-synaptic densityPeripheral signatureMolecular basisProteomic profilesProteinMarkers of neuropathologyBrain tissue samplesSynaptic pathologyVesiclesSynaptic integrityImmunoaffinity methodUse disordersFunctional integrityImportant insightsNeuropathologyPilot study
2015
The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients
Wilkinson ST, van Schalkwyk GI, Davidson L, D’Souza D. The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. Psychiatric Quarterly 2015, 87: 177-187. PMID: 25982082, DOI: 10.1007/s11126-015-9369-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMarijuana SmokingMiddle AgedRisk AssessmentSubstance-Related DisordersVeteransYoung AdultConceptsRisk perceptionSubstance usersIndividual experiencesSample of substanceNegative social consequencesSubstance abuse problemsMarijuana risk perceptionsInductive thematic analysisMarijuana useSemi-structured interviewsPhysical withdrawalSubstance abuseAbuse problemsPerceptionSocial consequencesBehavioral effectsMarijuanaOvert behavioral effectsThematic analysisProminent perspectivesSources of informationParticipantsVeteransExperiencePrevious literature
2013
Spicing things up: synthetic cannabinoids
Spaderna M, Addy PH, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013, 228: 525-540. PMID: 23836028, PMCID: PMC3799955, DOI: 10.1007/s00213-013-3188-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCannabinoidsDesigner DrugsHumansIllicit DrugsLegislation, DrugSubstance Abuse DetectionSubstance-Related Disorders
2006
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia
Krystal JH, D’Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10: 235-252. PMID: 17197373, DOI: 10.1007/bf03033360.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismComorbidityDiagnosis, Dual (Psychiatry)HumansMotivationRiskSchizophreniaSchizophrenic PsychologySubstance-Related DisordersConceptsSubstance abuse riskSubstance abuseSubstance abuse disordersAbuse riskSubstances of abuseNicotinic cholinergicPatient groupDopaminergic inputAbused substancesAbuse disordersSchizophrenic patientsDysphoric effectsAbuse liabilityHigh dosesLow dosesNegative symptomsReceptor functionAltered responseSchizophreniaSchizophrenic individualsRiskReward processingSubjective distressImpulsive behaviorDoses
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness